J Clin Neurol.  2017 Oct;13(4):444-446. 10.3988/jcn.2017.13.4.444.

Tafamidis for a Transplant Patient with Transthyretin Amyloid Polyneuropathy

• Romero-Imbroda J
• Sagrario-Fustero T
• Del Canto-Pérez C

• KMID: 2392148
• DOI: http://doi.org/10.3988/jcn.2017.13.4.444

Abstract

No abstract available.

MeSH Terms

Amyloid Neuropathies*
Amyloid*
Humans
Prealbumin*
Amyloid
Prealbumin

Figure

• 

  Fig. 1 The figure shows scores on (A) NIS-LL, (B) NQOL, (C) Karnofsky Performance Scale Index of functional impairment, (D) R-ODS score scales and (E) mBMI. mBMI: Body Mass Index modified by total protein, NIS-LL: Neuropathy Impairment Score-Lower Limbs, NQOL: Norfolk Quality of Life-Diabetic Neuropathy Questionnarire, R-ODS: Rasch-built Overall Disability Scale.

Reference

1. Hund E, Linke RP, Willig F, Grau A. Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment. Neurology. 2001; 56:431–435.

2. Benson MD. Liver transplantation and transthyretin amyloidosis. Muscle Nerve. 2013; 47:157–162.

3. Said G, Planté-Bordeneuve V. Familial amyloid polyneuropathy: a clinico-pathologic study. J Neurol Sci. 2009; 284:149–154.

4. Sekijima Y, Yazaki M, Oguchi K, Ezawa N, Yoshinaga T, Yamada M, et al. Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis. Neurology. 2016; 87:773–781.

5. Liepnieks JJ, Zhang LQ, Benson MD. Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology. 2010; 75:324–327.

6. Coelho T, Maia LF, da Silva AM, Cruz MW, Planté-Bordeneuve V, Suhr OB, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013; 260:2802–2814.

7. Sekijima Y. Transthyretin-type cerebral amyloid angiopathy: a serious complication in post-transplant patients with familial amyloid polyneuropathy. J Neurol Neurosurg Psychiatry. 2015; 86:124.

8. Benson MD, Smith RA, Hung G, Kluve-Beckerman B, Showalter AD, Sloop KW, et al. Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment. Amyloid. 2010; 17:43–49.